Galera Therapeutics (GRTX) AI Stock Analysis

• Market Cap: $2.49M
• Dividend Yield: N/A
• Average Volume (3M): 63.57K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.85
• Revenue Growth: N/A
• EPS Growth: 63.89%
• Country: US
• Employees: 3
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 75,462,390
• 10 Day Avg. Volume: 87,114
• 30 Day Avg. Volume: 63,573
• PEG Ratio: <0.01
• Price to Book (P/B): -0.02
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.21
• Enterprise Value/Market Cap: -0.46
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: 0.30
• Enterprise Value/Ebitda: 0.12
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: $0.02 ▲(15.00% Upside)
• Action: Upgraded Date: 12/30/25
• Date: Action: Upgraded 12/30/25

The score is primarily held down by fragile financial fundamentals—no revenue, continuing losses, negative free cash flow, and especially the stressed balance sheet with negative equity and a large debt increase. Technical signals are also weak (negative MACD and sub-50 RSI), while valuation is constrained by unprofitability and lack of dividend support.

Positive Factors

Reduced cash burn in 2024

The sharp improvement in operating cash flow and free cash flow in 2024 materially extends runway versus 2023 levels. This durable reduction in cash burn reflects tighter cost control and improved cash conversion, lowering near-term refinancing risk and improving strategic optionality.

Focused clinical-stage niche

A clear, specialized focus on protecting normal tissues during radiotherapy targets a persistent unmet medical need. This structural niche sustains long-term demand and can attract strategic partnerships or licensing, creating durable optionality even absent near-term commercial revenue.

Asset sale shifted liabilities to buyer

The sale of dismutase mimetic assets and transfer of associated liabilities to Biossil is a structural balance-sheet event. By offloading obligations (including Blackstone-related ones), Galera reduces contingent risks and financing pressure, materially improving solvency profile going forward.

Negative Factors

Deeply negative equity and large debt spike

Negative equity combined with a step-change in leverage sharply raises solvency and refinancing risk. With assets of only ~$10M, the company has limited collateral or flexibility, making sustained operations vulnerable to credit market access and adverse covenant or liquidity shocks.

No revenue and ongoing operating losses

Absence of product revenue means the business is entirely dependent on financing or asset transactions to fund R&D and operations. Persistent material losses erode flexibility and make long-term viability contingent on successful partnerships, asset sales, or new financing.

Negative free cash flow, reliance on external financing

Although cash burn improved, free cash flow remains negative, implying ongoing external funding needs. This structural dependence increases dilution or debt risk, and sustained negative FCF limits the company's ability to invest in development without recurring financing events.

Galera Therapeutics Business Overview & Revenue Model

Company Description

Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also involved in developing GC4711, a superoxide dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

How the Company Makes Money

Galera Therapeutics primarily makes money through the development and commercialization of its drug candidates. As a clinical-stage company, its revenue model is largely centered on successful clinical trials leading to regulatory approvals and subsequent commercialization of its products. Revenue streams may include milestone payments, licensing agreements, and potentially sales revenue once its therapeutics receive regulatory approval. Additionally, Galera may engage in strategic partnerships with larger pharmaceutical companies to enhance the development and distribution of its therapies, which could also contribute to its financial earnings.

Galera Therapeutics Financial Statement Overview

Summary

Financials remain very weak: no revenue, ongoing losses and negative free cash flow. The balance sheet is the largest risk with deeply negative equity and a sharp jump in debt versus a small asset base, raising solvency/financing concerns. A positive offset is the meaningful reduction in net loss and cash burn in 2024.

Income Statement

The company has generated no revenue across the provided annual periods, while losses remain material (net loss of about $19.0M in 2024 vs. ~$59.1M in 2023). Operating profitability is deeply negative (EBIT and EBITDA losses), indicating the business is still fully reliant on funding rather than commercial operations. A key positive is the sharp reduction in annual net loss in 2024, but the lack of revenue and persistent negative gross profit keep the earnings quality and sustainability weak.

Balance Sheet

The balance sheet is highly stressed: stockholders’ equity is negative in 2021–2024 (about -$143.7M in 2024), and total debt surged to ~$151.0M in 2024 from ~$1.25M in 2023. Total assets are low (~$10.1M in 2024), which limits financial flexibility and increases refinancing/solvency risk. While prior years showed stronger equity levels (2019–2020), the deterioration into deeply negative equity and the step-change in leverage are major red flags.

Cash Flow

Cash burn remains significant, but improved: operating cash flow was about -$12.1M in 2024 versus roughly -$44.8M in 2023, and free cash flow improved similarly (about -$12.1M in 2024). Free cash flow also tracked net losses closely (free cash flow-to-net income ~1x), suggesting losses are largely reflected in cash usage rather than being heavily distorted by non-cash items. The main weakness is that free cash flow is still negative, meaning continued dependence on external financing.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-3.83M	-3.84M	-259.00K	-114.00K	-778.00K	-368.00K
EBITDA	-9.55M	-20.16M	-70.24M	-50.61M	-72.56M	-69.01M
Net Income	-8.99M	-18.96M	-59.08M	-62.22M	-80.53M	-74.22M
Balance Sheet
Total Assets	5.00M	10.10M	26.14M	44.04M	83.31M	84.10M
Cash, Cash Equivalents and Short-Term Investments	4.47M	8.29M	18.26M	31.60M	71.22M	72.78M
Total Debt	0.00	151.05M	1.25M	44.00K	302.00K	534.00K
Total Liabilities	151.65M	153.77M	157.33M	153.22M	141.31M	77.98M
Stockholders Equity	-146.65M	-143.67M	-131.19M	-109.18M	-58.00M	6.12M
Cash Flow
Free Cash Flow	-2.34M	-12.14M	-44.91M	-43.45M	-68.24M	-59.99M
Operating Cash Flow	-2.34M	-12.14M	-44.85M	-43.43M	-67.96M	-59.54M
Investing Cash Flow	-50.00K	-46.00K	27.29M	23.99M	5.24M	36.55M
Financing Cash Flow	2.86M	2.22M	31.50M	3.89M	66.71M	20.51M

Galera Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.02
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GRTX, the sentiment is Positive. The current price of 0.02 is below the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.02, and below the 200-day MA of 0.02, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 99.58 is Negative, neither overbought nor oversold. The STOCH value of 68.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GRTX.

Galera Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
EVAX	50 Neutral	$21.92M	-0.37	―	―	4455.07%	77.31%
SCNI	49 Neutral	$732.72K	-0.07	―	―	178.82%	-4121.10%
GRTX	41 Neutral	$2.49M	-0.25	13.71%	―	―	63.89%
ONCO	33 Underperform	$1.08M	>-0.01	-263.57%	―	-34.58%	96.41%